Summit Therapeutics plans to file for approval for its closely watched lung cancer treatment by the end of this year, even though US drug regulators already warned the company it doesn’t have strong enough data https://t.co/x1Wm9t8fAB ...

Group 1 - AIM ImmunoTech Inc. is recognized as a fundamentally strong penny stock with a 'Buy' rating and a price target of $6.00, indicating a potential upside of nearly 133% [1] - The company presented positive progress from its Ampligen clinical program in pancreatic cancer at a recent symposium, highlighting its ongoing research efforts [2] - CEO Thomas K. Equels emphasized the potential of Ampligen for treating late-stage metastatic and locally advanced pancreatic cancer, addressing a significant unmet medical need [3] Group 2 - AIM ImmunoTech is an immuno-pharma company based in Ocala, Florida, focusing on developing solutions for various cancers, viral diseases, and immune deficiency disorders [3]

Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information does not constitute any recommendation or advice for investment actions [1]. - Users are advised to consider their financial situation and needs before relying on the information provided [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - It encourages users to perform their own research and understand the risks involved before investing in any financial instruments [1].

Stock Recommendations - Open Door was considered a speculative stock pick, initially bought at $1.71, with advice to "ring the register" to avoid meme stock territory [2] - Terra Wolf is considered a low-quality stock to avoid [3] - Hubble is viewed as a fantastic American industrial company, recommended to stay long, but to wait for a price dip before buying more [4][5] - Lumenum Holdings experienced an upside explosion after years of stagnation; the recommendation is to sell half the position on Monday morning and play with the "house's money" [5][6] - Summit Therapeutics' drug for cancer screening had bad news, and the recommendation is to move on, as it's unlikely to recover [7] General Investment Strategy - The focus is on high-quality stocks [3] - Insider buying is noted, but there's no rush to exit the position, although the speaker is not enthusiastic about it [8] Program Information - The Lightning Round is sponsored by Charles Schwab [8] - Viewers can follow Jim Kramer on X (formerly Twitter) and use madmentions to ask questions [8] - Viewers can send emails to madmoney@cnbc.com or call 1-800-743-CNNBC [8] - Missed segments can be found at madmoney.cnbc.com [9]

Core Insights - 康方生物's stock rose over 4%, specifically 4.39%, reaching 133.3 HKD with a trading volume of 288 million HKD [1] Group 1: Clinical Research Results - 康方生物's overseas partner, Summit Therapeutics, presented updated data from the global multicenter Phase III HARMONi study at the 2025 WCLC Presidential Symposium, indicating an improvement in overall survival (OS) with a hazard ratio (HR) of 0.78 (P=0.0332) [1] - The updated OS data shows a positive trend compared to the analysis from May, particularly highlighting a significant benefit in the North American population with an HR of 0.70 [1] Group 2: Clinical Performance and Market Value - 中信建投 noted that both the international Phase III HARMONi study and the Phase III HARMONi-A study conducted in China demonstrated excellent clinical performance in progression-free survival (PFS) and OS [1] - The results confirm that the依沃西 therapy not only has rapid efficacy and effective disease control but also exhibits a favorable tail effect in tumor immunotherapy, emphasizing its consistent benefits and safety across different regions and ethnicities [1]

Core Viewpoint - 康方生物's stock rose over 4%, reaching 133.3 HKD with a trading volume of 288 million HKD, following the release of updated data from the HARMONi study at the 2025 WCLC conference [1] Group 1: Clinical Study Results - 康方生物's partner, Summit Therapeutics, presented updated data from the global multicenter Phase III HARMONi study, showing an improvement in overall survival (OS) with a hazard ratio (HR) of 0.78 (P=0.0332) [1] - The updated OS data indicates a positive trend compared to the analysis from May, particularly highlighting a significant benefit in the North American population with an HR of 0.70 [1] Group 2: Treatment Efficacy - 中信建投 noted that the HARMONi study results, along with the Phase III HARMONi-A study conducted in China, demonstrated excellent clinical performance in both progression-free survival (PFS) and OS [1] - The findings confirm that the依沃西 therapy offers rapid efficacy and effective disease control, along with a favorable tail effect in tumor immunotherapy [1] Group 3: Global Market Potential - The consistent benefit trends and safety profiles observed in both global and Chinese clinical settings further emphasize the global market value of 依沃西 [1]

Akeso’s shares slump after US partner Summit Therapeutics unveiled new data that cast doubt on the future of their closely-watched lung cancer drug in America https://t.co/Xw84SxwFem ...

Core Insights - The global multi-center phase III clinical study HARMONi for AK112 (Evosinib) has successfully met its primary endpoint of progression-free survival (PFS) [1][2] - Evosinib is the world's first PD-1/VEGF dual antibody, showing potential to replace Merck's PD-1 drug, Pembrolizumab, based on its superior PFS results in previous studies [1][2] - The study included 438 patients, with a significant portion (38%) from North America and Europe, indicating a diverse patient demographic [2] Group 1 - The HARMONi study demonstrated a statistically significant improvement in PFS with a hazard ratio (HR) of 0.52, while the overall survival (OS) showed a positive trend but did not reach statistical significance with an HR of 0.79 (p=0.057) [2] - The updated data from Summit Therapeutics revealed an improved OS HR of 0.78 (95% CI: 0.62–0.98, p=0.0332) after a median follow-up of 13.7 months, indicating a notable enhancement in survival outcomes [3] - The results from the international HARMONi study align with the domestic HARMONi-A study, showcasing consistent clinical performance in both PFS and OS, highlighting Evosinib's global market potential [4] Group 2 - The chairman of the company expressed strong confidence in AK112 despite the stock price fluctuations, emphasizing the importance of clinical validation in the development of dual antibodies [2][3] - The study's findings underscore the therapeutic advantages of Evosinib, including rapid efficacy and effective disease control, as well as a favorable immune therapy tail effect [4] - The data from the North American cohort showed significant survival benefits, with the control group having a median OS of 14.0 months and an HR of 0.70, further supporting the drug's efficacy [3]

Core Viewpoint - 康方生物's stock rose over 4%, currently at 164.6 HKD with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody drug, Ivoris, during the conference, specifically the Phase III HARMONi study results, which have been selected for a Late-Breaking Abstract presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in patients with immune therapy-resistant lung cancer, which has been included in the Mini Oral session of the conference [1] - The combination therapy of Cardonili has previously been recognized as a breakthrough therapy for advanced squamous non-small cell lung cancer (NSCLC) after progression on PD-(L)1 inhibitors, highlighting its significant clinical value [1]

Core Viewpoint - 康方生物's stock rose over 4%, reaching 164.6 HKD with a trading volume of 1.404 billion HKD, following the announcement of significant clinical trial results to be presented at the 2025 World Lung Cancer Conference [1] Group 1: Clinical Developments - 康方生物's partner, Summit Therapeutics, will present the results of the global first PD-1/VEGF bispecific antibody drug, Ivoris, during the conference, specifically the results from the international multicenter Phase III clinical trial HARMONi, which has been selected for a Late-Breaking Abstract oral presentation [1] - The company will also disclose efficacy data for the combination therapy of Cardonili and Proxilumab (VEGFR2) in patients with immune therapy-resistant lung cancer, which has been included in the Mini Oral session of the conference [1] - The combination therapy of Cardonili has previously been recognized as a breakthrough therapy for advanced squamous non-small cell lung cancer (NSCLC) that has progressed after PD-(L)1 inhibitor treatment, highlighting its significant clinical value [1]